Rayner Acquires Stake in Reper to Drive R&D and Build Presence in Russia

Source: Rayner

Following a 4-year R&D collaboration on a novel hydrophobic IOL material, Rayner has acquired a stake in Reper, a material science and medical device company based in Russia.

Terms of the deal were not disclosed.

The new proprietary non-glistening material is the basis for RayOne Hydrophobic IOL, which was CE approved in 2018, and is a now a wholly owned asset of Rayner along with a novel, highly efficient production process, according to a company news release. In a recent clinical review published in CRST Europe, Kevin L. Waltz, MD, described the performance of the new IOL: “refractive outcomes were excellent, reflecting stable and predictable effective lens position.”

“Reper became an important partner for Rayner with several new and exciting R&D projects in the pipeline in cataract and beyond. I’m looking forward to a rich partnership in terms of building our market presence in Russia and bringing new innovations to the market,” Tim Clover, CEO of Rayner, said in the news release.

“In addition to our innovation projects, we now operate as a single company providing over a quarter of the IOLs in Russia and bringing new technology to patients as a local manufacturer. We value the expertise and scale of Rayner and see lots of opportunities as we grow together,” Viacheslav Agarkov CEO of Reper, said in the news release.



Related Content